Barry Investment Advisors LLC Has $510,000 Stake in Bristol-Myers Squibb (NYSE:BMY)

Barry Investment Advisors LLC trimmed its position in Bristol-Myers Squibb (NYSE:BMY) by 15.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 9,010 shares of the biopharmaceutical company’s stock after selling 1,612 shares during the period. Barry Investment Advisors LLC’s holdings in Bristol-Myers Squibb were worth $510,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. Mayflower Financial Advisors LLC boosted its position in Bristol-Myers Squibb by 38.0% in the 4th quarter. Mayflower Financial Advisors LLC now owns 11,682 shares of the biopharmaceutical company’s stock valued at $661,000 after buying an additional 3,216 shares during the last quarter. BSW Wealth Partners boosted its position in shares of Bristol-Myers Squibb by 16.6% in the 4th quarter. BSW Wealth Partners now owns 9,540 shares of the biopharmaceutical company’s stock worth $540,000 after purchasing an additional 1,361 shares during the last quarter. Stonegate Investment Group LLC boosted its position in shares of Bristol-Myers Squibb by 1.9% in the 4th quarter. Stonegate Investment Group LLC now owns 27,666 shares of the biopharmaceutical company’s stock worth $1,565,000 after purchasing an additional 523 shares during the last quarter. Tamar Securities LLC boosted its position in shares of Bristol-Myers Squibb by 1.0% in the 4th quarter. Tamar Securities LLC now owns 418,110 shares of the biopharmaceutical company’s stock worth $23,648,000 after purchasing an additional 3,950 shares during the last quarter. Finally, Perigon Wealth Management LLC boosted its position in shares of Bristol-Myers Squibb by 23.8% in the 4th quarter. Perigon Wealth Management LLC now owns 60,093 shares of the biopharmaceutical company’s stock worth $3,388,000 after purchasing an additional 11,536 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Price Performance

Shares of NYSE BMY opened at $58.85 on Wednesday. The business’s 50 day moving average price is $57.55 and its two-hundred day moving average price is $52.85. The company has a market cap of $119.35 billion, a PE ratio of -16.39, a price-to-earnings-growth ratio of 2.02 and a beta of 0.45. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $61.10.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. The firm had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The business’s revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.00 earnings per share. On average, analysts predict that Bristol-Myers Squibb will post 0.92 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.21%. The ex-dividend date is Friday, January 3rd. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s payout ratio is currently -69.08%.

Analysts Set New Price Targets

Several research firms have weighed in on BMY. Barclays lifted their target price on Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an “underweight” rating in a report on Monday, October 7th. Cantor Fitzgerald reiterated a “neutral” rating and set a $50.00 target price on shares of Bristol-Myers Squibb in a report on Friday, October 18th. Bank of America reiterated a “neutral” rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th. Wolfe Research assumed coverage on Bristol-Myers Squibb in a research note on Friday, November 15th. They issued a “peer perform” rating on the stock. Finally, TD Cowen lifted their price target on Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $56.60.

Insider Transactions at Bristol-Myers Squibb

In related news, EVP Samit Hirawat purchased 1,830 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The stock was acquired at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the purchase, the executive vice president now owns 62,109 shares in the company, valued at approximately $3,395,499.03. This represents a 3.04 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the completion of the sale, the senior vice president now owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. This trade represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.